Evidence map›Paper›PMID 25740989›Full record

ArticleJournal of virology2015

Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers.

Wendy E Walker, Sebastian Kurscheid, Samit Joshi, Charlie A Lopez, Gerald Goh, Murim Choi, Lydia Barakat, John Francis, Ann Fisher, Michael Kozal and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2019
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Wendy E WalkerCenter of Excellence in Infectious Diseases, Department of Biomedical Sciences, TTUHSC El Paso, El Paso, Texas, USA Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Sebastian KurscheidSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Samit JoshiSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Charlie A LopezCenter of Excellence in Infectious Diseases, Department of Biomedical Sciences, TTUHSC El Paso, El Paso, Texas, USA.
Gerald GohDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
Murim ChoiDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
Lydia BarakatSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
John FrancisSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Ann FisherSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Michael KozalSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Heidi ZapataSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Albert ShawSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Richard LiftonDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA Howard Hughes Medical Institute, New Haven, Connecticut, USA.
Richard E SuttonSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA richard.sutton@yale.edu.
Erol FikrigSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA Howard Hughes Medical Institute, New Haven, Connecticut, USA.
Yale University · USHoward Hughes Medical Institute · USTexas Tech University Health Sciences Center · US

Funding

TRAINING IN THE PATHOGENESIS OF INFECTIOUS DISEASEST32AI007517 · NIAID · YALE UNIVERSITY · PI Jaimie Meyer, Albert C Shaw · 1997 to 2026
$6.1M
Midcareer Award in Translational Immunology of AgingK24AG042489 · NIA · YALE UNIVERSITY · PI SHAW, ALBERT C · 2012 to 2022
$1.8M
Investigating the genetic basis of CD4-intrinsic HIV controlR21AI102802 · NIAID · YALE UNIVERSITY · PI WALKER, WENDY ELIZABETH · 2013 to 2014
$411k
Howard Hughes Medical InstituteNIAID NIH HHS AI102802NIAID NIH HHS R21 AI102802NIAID NIH HHS T32 AI007517NIA NIH HHS AG042489NIA NIH HHS K24 AG042489
6 · The paper itself

Abstract

unlabelledElite controllers (ECs) are a rare group of HIV seropositive individuals who are able to control viral replication without antiretroviral therapy. The mechanisms responsible for this phenotype, however, have not been fully elucidated. In this study, we examined CD4(+) T cell resistance to HIV in a cohort of elite controllers and explored transcriptional signatures associated with cellular resistance. We demonstrate that a subgroup of elite controllers possess CD4(+) T cells that are specifically resistant to R5-tropic HIV while remaining fully susceptible to X4-tropic and vesicular stomatitis virus G (VSV-G)-pseudotyped viruses. Transcriptome analysis revealed 17 genes that were differentially regulated in resistant elite controllers relative to healthy controls. Notably, the genes encoding macrophage inflammatory protein 1α (MIP-1α), CCL3 and CCL3L1, were found to be upregulated. The MIP-1α, MIP-1β, and RANTES chemokines are natural ligands of CCR5 and are known to interfere with HIV replication. For three elite controllers, we observed increased production of MIP-1α and/or MIP-1β at the protein level. The supernatant from resistant EC cells contained MIP-1α and MIP-1β and was sufficient to confer R5-tropic resistance to susceptible CD4(+) T cells. Additionally, this effect was reversed by using inhibitory anti-MIP antibodies. These results suggest that the T cells of these particular elite controllers may be naturally resistant to HIV infection by blocking R5-tropic viral entry. IMPORTANCE: HIV is a pandemic health problem, and the majority of seropositive individuals will eventually progress to AIDS unless antiretroviral therapy (ART) is administered. However, rare patients, termed elite controllers, have a natural ability to control HIV infection in the absence of ART, but the mechanisms by which they achieve this phenotype have not been fully explored. This paper identifies one mechanism that may contribute to this natural resistance: some elite controllers have CD4(+) T cells that produce high levels of MIP chemokines, which block R5-tropic HIV entry. This mechanism could potentially be exploited to achieve a therapeutic effect in other HIV-seropositive individuals.

Indexed as

HIV-1HIV Long-Term SurvivorsAdultAgedCase-Control StudiesCD4-Positive T-LymphocytesChemokine CCL3Chemokine CCL4Chemokine CCL5Chemokines, CCCohort StudiesFemaleGene DosageHIV InfectionsHost-Pathogen InteractionsHumansCCL3L1 protein, humanCCL3 protein, humanCCL4 protein, humanCCL5 protein, humanCCR5 protein, humanChemokine CCL3Chemokine CCL4Chemokine CCL5Chemokines, CCCXCR4 protein, humanMacrophage Inflammatory ProteinsReceptors, CCR5Receptors, CXCR4RNA, Messenger

Identifiers

PMID25740989
PMCPMC4442529
OpenAlexW1995888498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.